fluoronorchloroepibatidine

Also Known As:

(18F)NEEP; (18F)fluoronorchloroepibatidine; 2-(6-fluoro-3-pyridyl)-7-azabicyclo(2.2.1)heptane; 6-(6-fluorpyridin-3-yl)-8-azabicyclo(3.2.1)octane; NCFHEB cpd; exo-2-(2'-(18F)fluoro-5'-pyridinyl)-7-azabicyclo(2.2.1)heptane; exo-2-(2'-fluoro-5'-pyridinyl)-7-azabicyclo(2.2.1)heptane; flubatine; fluoro-norchloroepibatidine; norchloro-fluoro-homoepibatidine

Networked: 6 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Brust, Peter: 4 articles (01/2021 - 04/2013)
2.	Fischer, Steffen: 4 articles (01/2021 - 04/2013)
3.	Hoepping, Alexander: 4 articles (01/2021 - 04/2013)
4.	Sabri, Osama: 4 articles (01/2021 - 04/2013)
5.	Smits, René: 4 articles (01/2021 - 04/2013)
6.	Deuther-Conrad, Winnie: 3 articles (01/2021 - 12/2016)
7.	Patt, Marianne: 3 articles (01/2021 - 12/2016)
8.	Steinbach, Jörg: 3 articles (01/2021 - 04/2013)
9.	Tiepolt, Solveig: 3 articles (01/2021 - 12/2016)
10.	Ludwig, Friedrich-Alexander: 2 articles (01/2021 - 02/2018)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 12/01/2016 - "In a previous preclinical study, the main advantage of (+)-[18F]flubatine compared to (-)-[18F]flubatine was its higher binding affinity suggesting that (+)-[18F]flubatine might be able to detect also slight reductions of α4β2 nAChRs and could be more sensitive than (-)-[18F]flubatine in early stages of Alzheimer's disease. " 02/20/2018 - "In a clinical study in patients with early Alzheimer's disease, (+)-[18F]flubatine ((+)-[18F]1) was examined regarding its metabolic fate, in particular by identification of degradation products detected in plasma and urine. " 01/01/2021 - "Aims were to develop a kinetic modeling-based approach to quantify (+)-[18F]Flubatine and compare the data of healthy controls (HCs) and patients with Alzheimer's disease (AD); to investigate the partial volume effect (PVE) on regional (+)-[18F]Flubatine binding; and whether (+)-[18F]Flubatine binding and cognitive test data respective β-amyloid radiotracer accumulation were correlated. " 01/01/2021 - "(+)-[18F]Flubatine as a novel α4β2 nicotinic acetylcholine receptor PET ligand-results of the first-in-human brain imaging application in patients with β-amyloid PET-confirmed Alzheimer's disease and healthy controls." 11/01/2016 - "The positron emission tomography (PET) radioligand (-)-[(18)F]flubatine is specific to α4β2(⁎) nicotinic acetylcholine receptors (nAChRs) and has promise for future investigation of the acetylcholine system in neuropathologies such as Alzheimer's disease, schizophrenia, and substance use disorders. "
2.	Substance-Related Disorders (Drug Abuse) 11/01/2016 - "The positron emission tomography (PET) radioligand (-)-[(18)F]flubatine is specific to α4β2(⁎) nicotinic acetylcholine receptors (nAChRs) and has promise for future investigation of the acetylcholine system in neuropathologies such as Alzheimer's disease, schizophrenia, and substance use disorders. "
3.	Schizophrenia (Dementia Praecox) 11/01/2016 - "The positron emission tomography (PET) radioligand (-)-[(18)F]flubatine is specific to α4β2(⁎) nicotinic acetylcholine receptors (nAChRs) and has promise for future investigation of the acetylcholine system in neuropathologies such as Alzheimer's disease, schizophrenia, and substance use disorders. "
4.	Neurodegenerative Diseases (Neurodegenerative Disease) 04/01/2013 - "(-)-[(18)F]flubatine is a promising agent for visualization by PET of cerebral α4β2 nicotinic acetylcholine receptors (nAChRs), which are implicated in psychiatric and neurodegenerative disorders. "
5.	Obesity 12/01/2022 - "We studied 15 non-smoking individuals with obesity (body mass index, BMI: 37.8 ± 3.1 kg/m2; age: 39 ± 14 years, 9 females) and 16 normal-weight controls (non-smokers, BMI: 21.9 ± 1.7 kg/m2; age: 28 ± 7 years, 13 females) by using PET and the α4β2* nAChR selective (-)-[18F]flubatine, which was applied within a bolus-infusion protocol (294 ± 16 MBq). "

Related Drugs and Biologics

1.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
2.	Acetylcholine (Acetylcholine Chloride)
3.	Ligands
4.	Amyloid (Amyloid Fibrils)